Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Loestrin 24 Fe Ad Campaign Targets Consumers Not Currently On Birth Control

This article was originally published in The Pink Sheet Daily

Executive Summary

Ads for Warner Chilcott’s 24-day oral contraceptive debuted May 15, directing consumers to studies demonstrating a shorter period duration.

You may also be interested in...

Berlex’ YAZ Clears FDA For Contraception; April Launch Planned

A premenstrual dysphoric disorder indication for the low-dose version of Yasmin is still pending.

Loestrin 24 Approved As First 24-Day Oral Contraceptive

Warner Chilcott beats out Berlex' Yaz as the first oral contraceptive approved in the U.S. with 24 active hormone days.

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts